The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.
Keiji HiraiJunki MorinoSaori MinatoShohei KanekoKatsunori YanaiYuko MutsuyoshiHiroki IshiiMomoko MatsuyamaTaisuke KitanoMitsutoshi ShindoAkinori AomatsuHaruhisa MiyazawaKiyonori ItoYuichiro UedaSusumu OokawaraYoshiyuki MorishitaPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
Using SGLT-2 inhibitors as an add-on therapy may have beneficial effects on renal function in patients with advanced-stage diabetic kidney disease taking RAS blockers without any adverse effects.